Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

The List: Innovative Models On Which To Build Biotech

Aug. 3, 2005

By Cynthia Robbins-Roth

Building Biotechnology But Not Via Biotech Companies

Aug. 2, 2005

By Cynthia Robbins-Roth

Building Biotechnology But Not Via Biotech Companies

Aug. 2, 2005

By Cynthia Robbins-Roth

BIO's Past President Mulls Biotech's Path Into Future

June 20, 2005

By Cynthia Robbins-Roth

BIO's Past President Mulls Biotech's Path Into Future

June 20, 2005

By Cynthia Robbins-Roth

Broken? Readers Comment On Biotechnology Hurdles

May 31, 2005

By Cynthia Robbins-Roth

Biotech Model Broken; Now What Can Be Done About It?

May 3, 2005

By Cynthia Robbins-Roth

Biotech Model Broken; Now What Can Be Done About It?

May 3, 2005

By Cynthia Robbins-Roth

Lower IPO Valuations Quashing Early VC Biotechnology Funding

May 2, 2005

By Cynthia Robbins-Roth

Lower IPO Valuations Quashing Early VC Biotechnology Funding

May 2, 2005

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 4, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Phase III AMD miss leaves BLA Outlook same with bevacizumab
BioWorld
Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.